跳至主要内容
临床试验/JPRN-jRCTs031180051
JPRN-jRCTs031180051进行中(未招募)未知

Prospective observational study for Treatment resistance related gene screening using plasma circulating tumor DNA in the third generation EGFR-TKI Osimertinib therapy - Elucidator

Tamiya Akihiro0 个研究点目标入组 180 人开始时间: 2018年12月10日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Cases in which a definitive diagnosis of non-squamous non-small cell lung cancer has been obtained by histological examination or cytological examination.
  • 2) Cases of inoperable or recurrent non-small cell lung cancer positive for EGFR-TKIs susceptibility gene mutation.
  • 3) Cases in which osimertinib monotherapy is used as the initial treatment.
  • 4) Plasma samples can be submitted.
  • 5) Written consent has been obtained.

排除标准

  • 1) Cases that the doctor in charge deems inappropriate for this study
  • 2) Cases with experience of allogeneic bone marrow transplantation
  • 3) Cases scheduled for non-leukocyte depletion whole blood transfusion
  • 4) Cases where the consent of the person cannot be obtained
  • 5) Minors under the age of 20
  • 6) Cases of inoperable or recurrent non-small cell lung cancer with negative EGFR-TKIs susceptibility gene mutations (without exon19del, exon21L858R)
  • 7) Cases less than 1 year after postoperative chemotherapy
  • 8) Cases of treatment containing drugs other than osimertinib

研究者

发起方
Tamiya Akihiro

相似试验